RecruitingPhase 2NCT04865887

Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

A Phase II Trial of Combination Therapy of Pembrolizumab and Lenvatinib in Patients With Locally Advanced or Metastatic Cervical Cancer

Sponsor

Georgetown University

Enrollment

35 participants

Start Date

Oct 7, 2022

Study Type

INTERVENTIONAL

Conditions

Cervical Cancer Metastatic Cervical Cancer

Summary

This is a phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer that had failed first line of therapy. The hypothesis is the combination of lenvatinib and pembrolizumab will overcome vascular endothelial growth factor (VEGF)-mediated immunosuppression to enhance the response of patients with locally advanced or metastatic cervical cancer.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing the combination of pembrolizumab (an immunotherapy drug) and lenvatinib (a targeted therapy) in women with advanced or metastatic cervical cancer that has worsened or not responded to at least one prior treatment. **You may be eligible if...** - You are a woman aged 18 or older - You have been diagnosed with locally advanced or metastatic cervical cancer (confirmed by biopsy) - Your cancer has progressed or you could not tolerate at least one prior line of treatment - You are not pregnant or breastfeeding **You may NOT be eligible if...** - You have not yet received any prior treatment for advanced/metastatic cervical cancer - You are pregnant or breastfeeding - You have certain serious health conditions that prevent safe participation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.